Observational studyBMC emergency medicine2025
Real-world experience with vernakalant in the urgent management of atrial fibrillation: results from the VERITA study.
Observational study in BMC emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Intravenous vernakalant for acute termination of recent-onset atrial fibrillation in the emergency department.Heart rhythm O2 · 2026Article
- Vernakalant: Wish you were here.Heart rhythm O2 · 2026Article
- Comparative effectiveness and safety of vernakalant, flecainide, and amiodarone for atrial fibrillation cardioversion: a propensity score-matched analysis.BMC emergency medicine · 2026Observational
- Pharmacological Cardioversion Versus Electrical Cardioversion in the Acute Treatment of Atrial Fibrillation in the Emergency Department: The Recufa-Hula Register.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common arrhythmia encountered in hospital emergency departments (EDs), with pharmacological cardioversion being an effective strategy for restoring sinus rhythm in hemodynamically stable patients. This retrospective observational study aimed to evaluate the effectiveness and safety of vernakalant for the conversion of recent-onset AF under real-world clinical practice conditions, as well as to identify predictors of therapeutic response and adverse events. A total of 263 episodes of AF treated with vernakalant between 2012 and 2022 were analyzed. The overall cardioversion rate was 76.4%, with a median time to conversion of 15 minutes. Administration of the drug more than 12 hours after symptom onset was an independent predictor of therapeutic failure (OR: 4.5; 95% CI: 2.2-9.1; p < 0.001). The incidence of adverse events was 15.2%, occurring more frequently in patients with heart failure or when vernakalant was administered more than 24 hours after symptom onset. No deaths were reported. These findings support the effectiveness and safety profile of vernakalant in the ED setting, highlighting the importance of early administration and underlying cardiovascular comorbidities as key factors influencing therapeutic response and the risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.